Journal
TUMOR BIOLOGY
Volume 35, Issue 10, Pages 10571-10579Publisher
SPRINGER
DOI: 10.1007/s13277-014-2356-4
Keywords
FGF2-binding peptide; Cell proliferation; Cell cycle; Signaling pathway; Multi-targets
Categories
Funding
- National Natural Science Foundation of China [81102310, 81272462, 81101712]
- Natural Science Foundation of Zhejiang Province of China [Y4110029]
- Technology Foundation for Medical Science of Zhejiang Province [2012KYA127]
- Fundamental Research Funds for the Central Universities
- Guangdong Provincial Thousand-Hundred-Ten Talent Project
- Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Jinan University
- National Undergraduate Training Programs for Innovation and Entrepreneurship [201310343001]
Ask authors/readers for more resources
Some fibroblast growth factors (FGFs) play a critical role in tumorigenesis and progression. Among them, FGF2 was highly expressed in some tumors, and antagonists binding to FGF2 can suppress the growth of tumor cells. Therefore, FGF2 has been considered as an important target in cancer therapy. In this study, we identified a novel FGF2-binding short peptide (P8, PLLQATAGGGS-NH2) using phage display technology and alanine scanning. The P8 peptide suppressed FGF2-induced proliferation with no cytotoxic effect on cells, arrested the cycle at the G0/G1 phase in B16-F10 cells, and downregulated the activation of fibroblast growth factor receptor substrate 2 alpha (FRS2 alpha)/ERK cascade in B16-F10, NIH-H460, and SGC-7901 cells. Besides, P8 peptide can also inhibit the phosphorylation of FRS2 alpha stimulated by FGF1 and KGF2. These implied that P8 peptide may develop as a multi-target antagonist peptide contributing to tumor treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
